Idiopathic pulmonary fibrosis
Therapeutic area
Infectious Disease
Rare disease
Yes
- Definition
- An interstitial lung disease with a poor prognosis, that is characterized by the progressive formation of scar tissue within the lungs in the absence of any known cause.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Idiopathic pulmonary fibrosis
- Therapeutic area
- Infectious Disease
- idiopathic pulmonary fibrosis
- IPF
- Severity
- Severe
- Acquired
- Inflammatory
- Infectious Disease
- Pulmonology
- MONDO ID
- MONDO:0800504
- Parent condition
- MONDO:0002429
Related records
Broader conditions (17)
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Idiopathic disease
- Idiopathic interstitial pneumonia
- Infectious disease
- Inflammatory disease
- Interstitial lung disease
- Lower respiratory tract disorder
- Lung disorder
- Pneumonia
- Pneumonitis
- Respiratory system disorder
- Respiratory tract infectious disorder
Trials (589)
- (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
- 129Xe Gas Exchange Imaging in IPF and cHP: A Reliability Study
- 23andMe IPF Research Study
- 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
- 68Ga-BMV101 PET/CT in Patients With Idiopathic Pulmonary Fibrosis
- 68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis
- A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
- A 3-part Study to Evaluate Safety, Tolerability, Food Effect and Drug-drug Interactions of RXC007 in Healthy Volunteers
- A Adaptive Design Clinical Trial to Evaluate the Efficacy and Safety of TDI01 Suspension in the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.
- A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)
- A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of RC010 Inhalation Powder in Healthy Participants
- A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis
- A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF)
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
- A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care
- A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis
- A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension
- A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
- A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of PMG1015
Approved drugs (3)
- Nintedanib esylate
- Pirfenidone
- Prednisolone sodium phosphate
Drugs in development (91)
- [18F]-FBA-A20FMDV2 Phase 1
- Acetylcysteine Phase 3
- Admilparant Phase 3
- Albuterol Phase 1
- Ambrisentan Phase 3
- Artesunate Phase 1
- Atezolizumab Phase 1
- Axatilimab Phase 2
- Azathioprine Phase 2
- Beclomethasone dipropionate Phase 2
- Belumosudil Phase 2
- Bersiporocin Phase 2
- Bersiporocin hydrochloride Phase 1
- Bexotegrast Phase 2
- BMS-986020 Phase 2
- Bosentan Phase 3
- C-188-9 Phase 2
- Carbon monoxide Phase 2
- Cudetaxestat Phase 2
- Cyclophosphamide Phase 3